Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: Microdialysis and electrophysiological studies

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 366, Issue 5, 2002, Pages 417-424

  Pietraszek, Małgorzata ^a   Gołembiowska, Krystyna ^a   Bijak, Maria ^a   Ossowska, Krystyna ^a   Wolfarth, Stanislaw ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Chronic treatment; Clozapine; Electrophysiology; Fronto parietal cortex; Glutamatergic transmission; Haloperidol; Microdialysis

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; ASPARTIC ACID; CLOZAPINE; DRINKING WATER; GLUTAMIC ACID; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; VERATRIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ELECTROPHYSIOLOGY; FRONTAL CORTEX; IN VIVO STUDY; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; PARIETAL LOBE; PATHOGENESIS; RAT; SCHIZOPHRENIA; ANIMAL; COMPARATIVE STUDY; FRONTAL LOBE; METABOLISM; METHODOLOGY; SECRETION; WISTAR RAT;

ANIMALS; ASPARTIC ACID; CLOZAPINE; ELECTROPHYSIOLOGY; FRONTAL LOBE; GLUTAMIC ACID; HALOPERIDOL; MALE; MICRODIALYSIS; PARIETAL LOBE; RATS; RATS, WISTAR;

EID: 0036032336     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-002-0619-x     Document Type: Article

References (57)

1. Abekawa T, Ohmori T, Ito K, Koyoma T (2000) D1 dopamine receptor activation reduces extracellular glutamate and GABA concentrations in the medial prefrontal cortex. Brain Res 867: 250-254
2. Arvanov VL, Liang X, Magro P, Roberts R, Wang RY (1999) A pre- and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur J Neurosci 11:2917-2934
3. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9:117-124
4. Banerjee SP, Zuck LG, Yablonsky-Alter E, Lidsky TI (1995) Glutamate agonist activity: Implications for antipsychotic drug action and schizophrenia. Neuroreport 6:2500-2504
5. Battaglia G, Monn JA, Schoepp DD (1997) In vitro inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY 354740 in rats. Neurosci Lett 229:161-164
6. Berman KF, Weinberger DR (1990) The prefrontal cortex in schizophrenia and other neuropsychiatric diseases: In vivo physiological correlates of cognitive deficits. In: Uylings HBM, Van Eden CG, De Bruin JPC, Corner MA, Feenstra MGP (eds) Progress in Brain Research, vol 85. Elsevier Science, pp 521-537
7. Buller AL, Larson HC, Schneider BE, Beaton JA, Morrisett RA, Monaghan DT (1994) The molecular basis of NMDA receptor subtypes: Native receptor diversity is predicted by subunit composition. J Neurosci 14:5471-5484
8. Burnet PWJ, Chen CPLH, McGowan S, Franklin M, Harrison PJ (1996) The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 73:531-540
9. Cohen BM, Tsuneizumi T, Baldessarini RJ, Campbell A, Babb SM (1992) Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology (Berl) 108:338-344
10. 3H]ifen-prodil binding in rat brain membranes. J Pharmacol Exp Ther 280:584-592
11. Daly DA, Moghaddam B (1993) Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152:61-64
12. Damask SP, Bovenkerk KA, De la Pena G, Hoversten KM, Peters DB, Valentine AM, Meador-Woodruff JH (1996) Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex. Brain Res Mol Brain Res 41:241-249
13. Deakin JFW, Slater P, Simpson MDC, Gilchrist AC, Skan WJ, Royston NC, Reynolds GP, Cross AJ (1989) Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 52:1781-1786
14. De Souza IEJ, McBean GJ, Meredith GE (1999) Chronic haloperidol treatment impairs glutamate transport in the rat striatum. Eur J Pharmacol 382:139-142
15. Fletcher EJ, MacDonald JF (1993) Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. Eur J Pharmacol 235:291-295
16. Gandolfi O, Dall'Olio R (1996) Modulatory role of dopamine on excitatory amino acid receptors. Prog Neuropsychopharmacol Biol Psychiatry 20:659-671
17. 3H]MK-801 binding sites in the rat brain: A side-preference action in cortical areas. Brain Res 762:216-218
18. Gołembiowska K, Dziubina A (2001) Involvement of adenosine in the effect of antidepressants on glutamate and aspartate release in the rat prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol 363:663-670
19. Herzman M, Reba RC, Kotlyarove EV (1990) Single photon emission computerized tomography in phencyclidine and related drug abuse. Am J Psychiatry 147:255-256
20. Ilyin VI, Whittemore ER, Guastella J, Weber E, Woodward RM (1996) Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol Pharmacol 50:1541-1550
21. Imperato A, Di Chiara G (1984) Trans-striatal dialysis coupled to reverse phase height performance liquid chromatography with electrochemical detection: A new method for the study of the in vivo release of endogenous dopamine and metabolites. J Neurosci 4:966-977
22. Ishimaru M, Kurumaji A, Toru M (1992) NMDA-associated glycine binding site increases in schizophrenic brains. Biol Psychiatry 32:379-381
23. Jardemark KE, Liang X, Arvanov V, Wang RY (2000) Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate. Neuroscience 100:1-9
24. Kahn RS, Davis KL (1995) New developments in dopamine and schizoprenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress. Raven, New York, pp 1193-1201
25. Keck PE Jr, Cowen BM, Baldessarini RJ, McElroy SL (1989) Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry 146:1289-1292
26. Kendrick SJ, Lynch DR, Pritchett DB (1996) Characterization of glutamate binding sites in receptors assembled from transfected NMDA receptor subunits. J Neurochem 67:608-616
27. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B (1980) Low cerebral fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:379-382
28. Knecht R, Chang J-Y (1986) Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino)-azobenzenesulfonyl chloride. Anal Chem 58:2375-2379
29. Laurie DJ, Seeburg PH (1994) Ligand affinities at recombinant N-methyl-D-asparate receptors depend on subunit composition. Eur J Pharmacol 268:335-345
30. Leveque J-C, Macias W, Rajadhyaksha A, Carlson RR, Barczak A, Kang S, Li X-M, Coyle JT, Huganir RL, Heckers S, Konradi C (2000) Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci 20:4011-4020
31. Luizada PV, Brown BI (1976) Clinical management of the phencyclidine psychosis. Clin Toxicol 9:539-545
32. Lynch DR, Gallagher MJ (1996) Inhibition of N-methyl-D-aspartate receptors by haloperidol: Developmental and pharmacological characterization in native and recombinant receptors. J Pharmacol Exp Ther 279:154-161
33. 1-adenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 367:197-206
34. 2A and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292:76-87
35. McCoy L, Richfield EK (1996) Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci Lett 213:137-141
36. Moghaddam B, Adams B (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352
37. Moghaddam B, Bunney BS (1993) Depolarization inactivation of dopamine neurons: Terminal release characteristics. Synapse 14:195-200
38. Murray AM, Waddington JL (1990) The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: Behavioural indices. Eur J Pharmacol 186:79-86
39. Narahashi T (1974) Chemical tools in the study of excitable membranes. Physiol Rev 54:813-889
40. Ossowska K (1995) The subsensitivity of striatal glutamate receptors induced by chronic haloperidol in rats. Eur J Pharmacol 294:685-691
41. Ossowska K, Pietraszek M, Wardas J, Nowak G, Wolfarth S (1999) Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn Schmiedebergs Arch Pharmacol 359:280-287
42. Paxinos G, Watson C (1998) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego
43. Schneider JS, Wade T, Lidsky TI (1998) Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum. Neuroreport 9:133-136
44. See RE, Lynch AM (1995) Chronic haloperidol potentiates stimulated glutamate release in caudate-putamen, but not in prefrontal cortex. Neuroreport 6:1795-1798
45. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133-152
46. Simpson MDC, Slater P, Royston MC, Deakin JFW (1992) Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effect of disease process and neuroleptic medication. Schizophr Res 6:41-48
47. Tarazi FI, Florijn WI, Creese I (1996) Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology (Berl) 128:371-379
48. Tascedda F, Blom JMC, Brunello N, Zolin K, Gennarelli M, Colzi A, Bravi D, Carra S, Racagni G, Riva MA (2001) Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 50:117-122
49. Timmerman W, Westerink BHC (1997) Brain microdialysis of GABA and glutamate: What does signify? Synapse 27:242-261
50. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ishikawa H, Kurumaji A, Takashima M, Mataga N, Ogawa A (1988) Neurotransmitters, receptors and neuropeptides in postmortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78:121-137
51. Toru M, Kurumaji A, Kumashiro S, Suga I, Tamashima M, Nishikawa T (1992) Excitatory amino acidergic neurons in chronic schizophrenic brain. Mol Neuropharmacol 2:241-243
52. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52:829-836
53. Ułas J, Nguyen L, Cotman CW (1993) Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. Neuroreport 4:1049-1051
54. Viyoch J, Ohdo S, Yukawa E, Higuchi S (2001) Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice. J Pharmacol Exp Ther 298:964-969
55. Williams K (1994) Mechanisms influencing stimulatory effects of spermidine at recombinant N-methyl-D-asparate receptors. Mol Pharmacol 46:161-168
56. Willins DL, Berry SA, Alsayegh L, Backstrom JR, Sanders-Bush E, Friedman L, Roth BL (1999) Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience 91:599-606
57. Yamamoto BK, Cooperman MA (1994) Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14:4159-4166